<?xml version="1.0" encoding="UTF-8"?>
<p>In spite of that, WHO disclosed that this vaccine is in fact being tested in UK in Phase I, II and III trials (
 <xref rid="B36" ref-type="bibr">36</xref>) and will be tested in a Phase III trial in Brazil on 2,000 volunteers. Consequently, contracts for large-scale fabrication have already been signed with the Public Laboratory of the Brazilian Ministry of Health Bio-Manguinhos. In Brazil, 30 million doses are intended to be produced by Bio-Manguinhos and another 100 million after the proven efficacy of the vaccine. At this point it is important to know which end-points of vaccine efficacy will be taken into consideration for such an important decision.
</p>
